Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Novartis Confirms Raid by Swiss Competition Authorities in Patent Use Probe

Published 09/15/2022, 04:02 AM
Updated 09/15/2022, 04:05 AM
© Reuters.
NOVN
-

By Scott Kanowsky 

Investing.com -- Novartis AG (SIX:NOVN) has confirmed that the Swiss competition commission (COMCO) has visited the Basel headquarters of the drugmaker in connection to an investigation over the potentially unlawful use of a dermatology patent.

COMCO officials carried out the raid on September 13, the watchdog said in a statement that did not name Novartis specifically. Regulators are looking into allegations that the firm tried to protect a treatment for skin diseases against competitors by using one of its patents to start legal proceedings.

In a separate statement, the company said the probe does not imply wrongdoing or have any financial impact on its operations. Novartis added that it is cooperating with the authorities and is confident that it will be able to "clarify the legitimacy of its position."

Shares in Novartis fell slightly in early European trading on Thursday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.